Literature DB >> 26116397

Systematic review and meta-analysis comparing hypofractionated with conventional fraction radiotherapy in treatment of early breast cancer.

Zhi-Rui Zhou1, Xin Mei1, Xing-Xing Chen1, Zhao-Zhi Yang1, Jing Hou1, Li Zhang1, Xiao-Li Yu2, Xiao-Mao Guo3.   

Abstract

BACKGROUND: The purpose of this meta-analysis is to evaluate the efficacy and safety of altered radiation fraction size on outcomes for early breast cancer patients.
METHODS: A search of MEDLINE, EMBASE, WEB OF SCIENCE, Cochrane Library and ClinicalTrials.gov was conducted. Quality of the randomized controlled trials (RCTs) or non-RCTs were evaluated according to Cochrane's risk of bias tool or Methodological Index for non-Randomized Studies (MINORS). Pooled risk ratio (RR) and 95% confidence interval (CI) were calculated. Subgroup analysis was applied according to different fraction dose and sensitivity analysis was performed according to RCTs or non-RCTs.
RESULTS: 23 studies were included in this systematic review. Meta-analysis demonstrated hypofractionation radiotherapy (HFRT) was associated with decreased grade 2/3 acute skin reactions compared with conventional fraction RT (CFRT), either 2.5-3.0 Gy per fraction or 5.0-6.5 Gy per fraction. HFRT with 2.5-3.0 Gy per fraction significantly decreased moderate/marked photographic changes in breast appearance compared with CFRT [RR = 0.80, 95% CI (0.70, 0.91), P = 0.001], while HFRT with more than 3.0 Gy per fraction significantly increased moderate/marked photographic changes [RR = 1.21, 95% CI (1.06, 1.38), P = 0.004]. In addition HFRT cost one-third lower than CFRT. Regarding to local regional recurrence, distant metastasis, overall survival, disease free survival, excellent/good cosmetic comes, symptomatic radiation pneumonitis, ischemic heart disease and symptomatic rib fracture, there was no significant difference between two arms.
CONCLUSIONS: Based on available evidence, HFRT with 2.5-3.0 Gy per fraction should be the better choice for treatment of early breast cancer patients.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Hypofractionation; Meta-analysis; Radiotherapy

Mesh:

Year:  2015        PMID: 26116397     DOI: 10.1016/j.suronc.2015.06.005

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  10 in total

Review 1.  Is internal mammary nodes irradiation as a part of breast cancer postoperative radiotherapy necessary?

Authors:  Zhi-Rui Zhou; Zhao-Zhi Yang; Xiao-Li Yu; Xiao-Mao Guo
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 2.  Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer.

Authors:  Montserrat Pazos; Stephan Schönecker; Daniel Reitz; Paul Rogowski; Maximilian Niyazi; Filippo Alongi; Christiane Matuschek; Michael Braun; Nadia Harbeck; Claus Belka; Stefanie Corradini
Journal:  Breast Care (Basel)       Date:  2018-05-24       Impact factor: 2.860

3.  Less increase of CT-based calcium scores of the coronary arteries : Effect three years after breast-conserving radiotherapy using breath-hold.

Authors:  M E Mast; M W Heijenbrok; M L van Kempen-Harteveld; A L Petoukhova; A N Scholten; R Wolterbeek; J H M Schreur; H Struikmans
Journal:  Strahlenther Onkol       Date:  2016-08-17       Impact factor: 3.621

Review 4.  Hypofractionated radiation treatment in the management of breast cancer.

Authors:  Apar Gupta; Nisha Ohri; Bruce G Haffty
Journal:  Expert Rev Anticancer Ther       Date:  2018-06-26       Impact factor: 4.512

5.  Comparison of the average surviving fraction model with the integral biologically effective dose model for an optimal irradiation scheme.

Authors:  Ryo Takagi; Yuriko Komiya; Kenneth L Sutherland; Hiroki Shirato; Hiroyuki Date; Masahiro Mizuta
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

Review 6.  Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era.

Authors:  David Azria; Ariane Lapierre; Sophie Gourgou; Dirk De Ruysscher; Jacques Colinge; Philippe Lambin; Muriel Brengues; Tim Ward; Søren M Bentzen; Hubert Thierens; Tiziana Rancati; Christopher J Talbot; Ana Vega; Sarah L Kerns; Christian Nicolaj Andreassen; Jenny Chang-Claude; Catharine M L West; Corey M Gill; Barry S Rosenstein
Journal:  Front Oncol       Date:  2017-04-27       Impact factor: 6.244

7.  Predictive parameters in hypofractionated whole-breast 3D conformal radiotherapy according to the Ontario Canadian trial.

Authors:  Grazia Lazzari; Angela Terlizzi; Giuseppina Della Vittoria Scarpati; Francesco Perri; Vincenzo De Chiara; Barbara Turi; Giovanni Silvano
Journal:  Onco Targets Ther       Date:  2017-03-24       Impact factor: 4.147

8.  Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lihu Gu; Wei Dai; Rongrong Fu; Hongfeng Lu; Jingyi Shen; Yetan Shi; Mengting Zhang; Ke Jiang; Feng Wu
Journal:  Front Oncol       Date:  2021-10-01       Impact factor: 6.244

9.  A radiobiological comparison of hypo-fractionation versus conventional fractionation for breast cancer 3D-conformal radiation therapy.

Authors:  Arezoo Kazemzadeh; Iraj Abedi; Alireza Amouheidari; Atefeh Shirvany
Journal:  Rep Pract Oncol Radiother       Date:  2021-02-25

10.  Individual Radiosensitivity as a Risk Factor for the Radiation-Induced Acute Radiodermatitis.

Authors:  Juras Kišonas; Jonas Venius; Olga Sevriukova; Mindaugas Grybauskas; Daiva Dabkevičienė; Arvydas Burneckis; Ričardas Rotomskis
Journal:  Life (Basel)       Date:  2021-12-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.